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ABSTRACT
Objective. Considering the high prevalence of epilepsy in the elderly and the importance of maximising their quality of life 
(QoL), this study aimed to investigate the relationship between medication adherence and QoL, and the mediating effects of 
medication adherence on the association between serum antiepileptic drug (AED) level and seizure severity with QoL in elderly 
epileptics.
Methods. In a longitudinal study, 766 elderly patients with epilepsy who were prescribed a minimum of one antiepileptic drug 
were selected by convenience sampling method. A Medication Adherence Report Scale (MARS-5) questionnaire was comple-
ted at the baseline. Seizure severity and QoL were assessed after six months using the Liverpool Seizure Severity Scale (LSSS) 
and the QoL in Epilepsy (QOLIE-31) questionnaires respectively. Serum level of AED was also measured at six-month follow-up. 
Results. Medication adherence was significantly correlated with both seizure severity (β = –0.33, p < 0.0001) and serum AED 
level (β = 0.29, p < 0.0001) after adjusting for demographic and clinical characteristics. Neither QoL nor its sub-classes were 
correlated with seizure severity. In addition, a significant correlation was not observed between serum AED level and QoL. 
However, medication adherence was significantly correlated with QoL (β = 0.30, p < 0.0001). The mediating effects of medica-
tion adherence on the association between serum AED level (Z = 3.39, p < 0.001) and seizure severity (Z = –3.47, p < 0.001) with 
QoL were supported by the Sobel test. 
 Conclusion. This study demonstrates that medication adherence has a beneficial impact on QoL in elderly epileptics. Therefore, 
adherence to treatment should be monitored to improve their QoL. 
Key words: epilepsy, medication adherence, seizure, quality of life, elderly 
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Introduction
Epilepsy, a neurological disorder characterised by recur-
rent unprovoked seizures, is one of the most common chronic 
brain disorders globally [1]. Despite advances in the under-
standing of  the pathophysiological mechanisms of epilepsy 
and the development of medical treatments in recent decades, 
people of all ages with this neurological disorder continue to 
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be stigmatised by it [2]. Epilepsy is one of the world’s longest-
-recognised medical conditions; it affects approximately 
50 million people worldwide with nearly 80% of them living 
in developing countries [3]. The prevalence of epilepsy in 
the Iranian population is between 7.8–18/1,000 persons or 
approximately 1.4% of the population [4, 5], which is slightly 
higher than the reported prevalence of 5.8–8.4/1,000 persons 
in developed countries [1, 6]. This disease affects all ages, 
ethnicities and socioeconomic groups; however, its prevalence 
and incidence increase markedly in individuals over the age 
of 65 years, even more than they do in infancy, another high 
prevalence age. In fact epilepsy is the third most common 
neurological disease in the elderly, after stroke and dementia 
[7, 8]. Taking into account  the future growth of the world’s 
population aged > 60 years [9] due to increasing life expec-
tancy, the prevalence of epilepsy is predicted to dramatically 
rise over the next few decades.
Medication adherence is a fundamental determinant of 
effective treatment [10] that is defined by the World Health 
Organisation as “the degree to which the person’s behaviour 
corresponds to the agreed recommendations from a health 
care provider” [11]. Epilepsy has been successfully controlled 
with medication adherence, and most people with epilepsy 
(almost 70% of patients) can become seizure-free by taking 
one anti-seizure medication daily, called an anti-epileptic drug 
(AED) [12, 13]. Nevertheless, non-adherence to medication is 
a very common phenomenon in patients with chronic diseases 
[14-18] including epilepsy [18–23], which not only affects the 
individual’s health but also the healthcare system. This leads 
to uncontrolled symptoms and substantial deleterious effects 
on the quality of life (QoL) and those patients can become 
a heavy burden on society and healthcare systems [24–26].
Elderly people with epilepsy generally respond well to AED 
treatment. Up to 80% of patients with late-onset epilepsy can 
be expected to remain seizure-free with AED treatment [27]; 
however, only 38–57% (average < 45%) of elderly epileptic 
patients have good adherence to AEDs [28]. Explanations 
for poor adherence in this population of patients include 
patient-physician discordance, complex medication regimen, 
the frequency of administration of multiple medications, 
disturbances of memory, specific beliefs about drugs, being 
depressed or anxious, and unusual times during the day to 
take the medication [25]. Although patient understanding  of 
the optimal care, and improving their QoL, are problematic in 
epileptic treatment, it remains questionable whether adher-
ence to AED can actually improve QoL in this population. 
The impact of AED therapy on the QoL in younger groups of 
patients has been previously reported [10, 29, 30] and posi-
tive and negative effects of AED therapy on QoL have been 
demonstrated [31]. However, the impact of AED treatment in 
terms of QoL among the elderly has not been well investigated. 
Therefore, the primary aim of this study was to assess the 
QoL and its correlation with AED adherence among elderly 
patients with epilepsy. In addition, we aimed to evaluate the 
mediating effects of medication adherence in the relationship 
between serum AED level and seizure severity with QoL. To 
obtain more accurate information on AED adherence, both 
a self-reporting method (Medication Adherence Report Scale, 
MARS-5) and serum AED level measurement were used. The 
correlation between MARS-5 score and serum AED level 
and whether MARS-5 score can be replaced with serum AED 
level to predict the QoL in the elderly with epilepsy was also 
examined.
Material and methods
Study design and participants 
This longitudinal study was carried out on 766 elderly 
patients with epilepsy referred to six neurology clinics between 
March 2014 and December 2015. The patients were recruited 
through convenience sampling. The subjects included males 
and females aged 65 years or above with a confirmed diagnosis 
of epilepsy according to the International League Against 
Epilepsy Criteria [32]. The subjects had the ability to per-
form daily activities, had been prescribed at least two AEDs, 
and had no major cognitive impairment (defined as a score 
of 23 or below on the Mental State Examination, MSE) or 
an acute psychiatric disorder diagnosed by a psychiatrist. 
Exclusion criteria were a history of drug abuse, diabetes, 
cardiovascular diseases, rheumatoid arthritis, malignant tu-
mours, kidney dysfunctions and liver diseases, being in receipt 
of medications other than AEDs at the time of recruitment 
or throughout the follow-up period, and being unwilling to 
participate in the study.
All applicants were screened by a trained physician for 
eligibility according to these inclusion and exclusion criteria. 
All eligible participants were given a full explanation of the 
objectives and protocol of the study, and written informed 
consent was signed prior to enrolment. Demographic charac-
teristics, clinical features and medication adherence were then 
collected from the participants. Six months later, the subjects 
were invited to attend the clinic to complete the questionnaires 
evaluating seizure severity and QoL. Blood samples were 
taken on the same day for the measurement of AED level as 
an objective assessment of AED adherence. 
Instruments
Background information sheet  
and medical records
Demographic characteristics including age, sex, marital 
status, educational years, employment and monthly income 
(High > $1,000; Intermediate = $500–1,000; Low < $500) 
were collected by face-to-face interviews and recorded in the 
Background Information Sheet. The clinical features of the 
participants, including the type of epilepsy and the duration 
of the disease, were also collected from their medical records.
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Medication Adherence Report Scale (MARS-5)
MARS-5 is a self-reporting and widely applicable question-
naire for the subjective assessment of medication adherence 
[33]. It consists of five statements of non-adherent behaviours 
(I forgot to take my antiepileptic medicine, I altered the dose 
of my antiepileptic medicine, I stopped taking my antiepileptic 
medicine for a while, I decided to miss a dose of my antiepileptic 
medicine, I took less antiepileptic medicines than prescribed) 
answered on a five-point Likert scale (1 = always, 2 = often, 
3 = sometimes, 4 = rarely, 5 = never), giving an overall score 
that ranges between 5 and 25. According to the threshold, 
a MARS-5 score of 20 or above is considered as high adherence 
[14]. The concurrent validity and internal consistency of the 
MARS-5 questionnaire has been supported by previous studies 
[34]. The participants completed the MARS-5 questionnaire 
at the baseline.
Liverpool Seizure Severity Scale (LSSS)
The participants were asked to complete the LSSS question-
naire if they reported more than one week had elapsed since 
their last seizure. The LSSS questionnaire consists of 20 items 
rated on a Likert scale. A four-point Likert scale was used to 
respond to each item, with higher points indicating greater 
seizure severity.  It has been demonstrated that LSSS is a valid 
and reliable instrument quantifying seizure severity that may 
also be used to evaluate changes in seizure severity over time 
[35]. Furthermore, the known-group validity showed subjects 
with severe seizure symptoms could be distinguished from 
those with minor seizure symptoms by LSSS [35]. 
Serum AED level
In order to measure serum concentrations at the six-
-month follow-up of the three most commonly used AEDs 
i.e. phenytoin, lamotrigine and carbamazepine, whole blood 
samples were taken prior to the next daily routine dose of 
drug. The serum was then separated, and AED concentrations 
were measured using a microparticle enzyme immunostimu-
latory assay kit (Abbott Axsym®, Abbott Laboratories, Abbott 
Park, IL, USA). The therapeutic dose range of AED which 
can prevent seizures effectively without toxic effects has been 
reported in detail [36]. The serum concentrations of AEDs 
were categorised into three groups based on the reference as 
‘below the therapeutic range’, ‘within the therapeutic range’, 
and ‘above the therapeutic range’. 
Quality of Life in Epilepsy (QOLIE-31)
QoL was evaluated using a QOLIE-31 questionnaire, 
which was designed exclusively to assess an epileptic patient’s 
QoL at six-month follow-up. It consists of 31 items in seven 
subclasses: seizure concerns, cognitive function, energy/
fatigue, emotional wellbeing, social function, medication 
efficacy, and overall QoL [37]. The subscale scores range from 
0 to 100 points, and the higher the score, the better the QoL. 
The overall score of QOLIE-31 can be calculated by weighting 
and summarising seven-dimension scores. The Persian version 
of QOLIE-31 has been shown to be a reliable instrument for 
assessing QoL in patients with epilepsy [38].
Statistical analysis
The results were expressed as mean ± standard deviation 
(SD) for quantitative data with normal distribution, and 
frequency (percent) for qualitative data. The analyses were 
performed in several steps. Firstly, Pearson correlation analysis 
was used to investigate the relationships between serum AED 
level, MARS-5 score, LSSS score, and overall QOLIE-31score. 
The relationships between serum AED level and LSSS score 
with the MARS-5 score were then evaluated by linear regres-
sion after adjusting for potential confounders (i.e. age, sex, 
marital status, education years, employment status, monthly 
income, type of epilepsy and disease duration). The relation-
ships between independent variables (serum AED level, LSSS 
and MARS-5 score) and dependent variable (each sub-class 
of QoL and the overall score of the QoL) were also evaluated 
using multiple linear regression analysis, after controlling for 
potential confounders. Based on the Bonferroni correction, 
p < 0.00625 (0.05/8) is considered as significant for multiple 
comparisons between the eight regression models.
Lastly, structural equation modelling (SEM) was used to 
test the model and investigate whether seizure severity and 
serum AED level directly correlated with the QoL, or whether 
it was being mediated through other factors. Several fit indices, 
including chi-square statistics, Comparative Fit Index (CFI), 
Goodness-of-Fit Index (GFI), Tucker–Lewis Index (TLI), Nor-
med Fit Index (NFI) and Root Mean Square Error of Approxi-
mation (RMSEA), were evaluated to determine the model fit. 
To interpret these indices, the following criteria were used: χ2/df 
ratio < 2 (excellent); χ2/df < 3 (good); χ2/df < 5 (acceptable); 
≥ 0.90 as good fit for CFI, GFI, TLI, and NFI; ≤ 0.08 as good 
fit for RMSEA[39]. Sobel test was also used to examine the 
significance of mediation effects. The descriptive analyses and 
regression models were performed using IBM SPSS version 
21.0 software; SEM was conducted using AMOS 21.
Results
The demographic and clinical characteristics of the parti-
cipants are set out in Table 1. The average age of participants 
was 73.9 ± 5.7 years, and more than half were female (54.7%). 
Most participants were married and had low levels of educa-
tion. All patients received polytherapy with a minimum of two 
AEDs. Therefore, it is not possible to assess the effect of each 
type of AED on adherence. As shown in Table 1, more than 
two-thirds of participants had focal epilepsy (70.2%). Of the 
patients with focal epilepsy, 97 (18%) reported focal seizures 
without impairment of consciousness, and 68 (13%) patients 
reported focal seizures with impairment of consciousness. 
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All patients with generalised epilepsy reported convulsive 
seizures.
The mean overall score of the QOLIE-31 among the 
participants was 67.8 ± 20.5, with energy/fatigue the worst 
domain (59.3 ± 18.6) and medication efficacy the best domain 
(78.7 ± 24.1) (Tab. 1). Furthermore, nearly half of the parti-
cipants (48.7%) had serum AED levels below the therapeutic 
range (i.e. categorised as non-adherent). 
In the first step, we investigated the relationship between 
the variables. All of the correlation coefficients were statisti-
cally significant. In particular, MARS-5 score was positively 
correlated with serum AED level (r = 0.36, p < 0.001), and 
inversely correlated with LSSS score (r = –0.39, p < 0.001). In 
addition, a positive correlation was observed between QO-
LIE-31 score and MARS-5 score (r = 0.33, p < 0.001). 
The relationships between the variables were then evalu-
ated by multiple linear regression after adjusting for potential 
confounders. Table 2 shows the results from the regression 
models that evaluated the association between MARS-5 score 
with LSSS score and serum AED level. As shown in Table 2, 
MARS-5 score was significantly correlated with both LSSS 
(β  =  –0.33, p < 0.0001) and serum AED level (β = 0.29, 
p < 0.0001) after adjusting for confounders.  In other words, 
LSSS and serum AED level were significant predictors of 
MARS-5 score and accounted for almost a quarter of the 
variation in the MARS-5 score.
The relationships between LSSS score, MARS-5 score and 
serum AED level with overall QOLIE-31 score and its domains 
are set out in Table 3. Neither overall QOLIE-31 score nor its 
sub-classes were correlated with LSSS score. Similarly, no signi-
ficant correlation was observed between serum AED level and 
overall QOLIE-31 score and the scores in QOLIE-31 domains 
after adjusting for demographic and clinical confounders. 
However, MARS-5 score was significantly correlated with 
the overall score of QOLIE-31 (β = 0.30, p < 0.0001) and its 
domains. 
After confirming the correlation between MARS-5 score 
and QOLIE-31 score, we tried to examine the proxy effects of 
MARS-5 on QoL using the SEM. The SEM analysis is graphi-
cally described in Figure 1. This model showed an acceptable 
fit. According to SEM analysis, all the goodness-of-fit indices 
indicated an acceptable fit, except for the χ2 which was stati-
stically significant (p < 0.001). However, the value of the χ2/df 
ratio was good (3.105 < 5). The rest of the fit indices showed 
an acceptable fit, with CFI, GFI, TLI and NFI above 0.9, and 
RMSEA less than 0.08 (CFI = 0.974, GFI = 0.978, TLI = 0.957, 
NFI = 0.963, RMSEA = 0.052). The standardised coefficients of 
LSSS score on QOLIE-31 score (-0.015) and serum AED level 
on QOLIE-31 (0.021) were not significant, while the standar-
dised coefficients of LSSS score on MARS-5 score (–0.316) and 
serum AED level on MARS-5 score (0.268) were significant. 
Furthermore, the mediating effects of MARS-5 score was 
investigated using the Sobel test. According to the Sobel test, 
LSSS (Z = –3.47, p < 0.001) and the serum AED level (Z = 3.39, 
Table 1. Demographic and clinical characteristics of the participants (n = 766)
Age (years) 73.94 ± 5.77
Male, n (%) 347 (45.3%)
Married, n (%) 582 (76.0%)
Education (years) 8.91 ± 5.10
Employed, n (%) 276 (36.0%)
Monthly income, n (%)
High (> $1,000) 162 (21.2%)
Intermediate ($500–1,000) 461 (60.2%)
Low (< $500) 143 (18.7%)
Epilepsy type, n (%)
Generalised 228 (29.8%)
Focal 538 (70.2%)
Aetiology, n (%)
Vascular 214 (28.0%)
Trauma  122 (15.9%)
Idiopathic/cryptogenic 430 (56.1%)
Type of medication, n (%)
Phenytoin 506 (66.0%)
Lamotrigine 333 (43.5%)
Carbamazepine 305 (39.8%)
Oxcarbazepine 204 (26.6%)
Phenobarbital 148 (19.3%)
Topiramate 73 (9.5%)
Primidone 42 (5.5%)
Zonisamide 33 (4.3%)
Gabapentin 28 (3.7%)
Seizure frequency 3.4 ± 3.2 
Disease duration (years) 17.71 ± 4.56
QOLIE-31score
Seizure concerns 77.16 ± 35.05
Cognitive function 66.45 ± 42.93
Energy/fatigue 59.33 ± 18.63
Emotional wellbeing 61.27 ± 18.92
Social function 78.00 ± 21.61
Medication efficacy 78.72 ± 24.12
Overall quality of life 61.77 ± 19.99
Overall score 67.81 ± 20.50
LSSS score 54.91 ± 23.46
MARS-5 score 13.32 ± 6.48
Serum AED level, n (%)
Below therapeutic range 373 (48.7%)
Within therapeutic range 295 (38.5%)
Above therapeutic range 98 (12.8%)
QOLIE-31 — Quality of Life in Epilepsy Inventory-31; LSSS — Liverpool Seizu-
re Severity Scale; MARS-5 — Medication Adherence Report Scale.
The data is expressed as mean ± SD unless specifically indicated.
Seizure frequency was defined as the mean frequency of complex partial 
seizures per month during six months of follow-up
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p < 0.001) showed indirect effects on QoL score. This means 
that the MARS-5 score can mediate the relationship between 
LSSS and QOLIE-31, as well as the relationship between AED 
level and QOLIE-31 (Fig. 1). However, LSSS score and serum 
AED level did not directly affect the QoL.
Discussion 
This study examined the associations among several 
variables that influence QoL in the elderly with epilepsy. We 
suggested a model for the effect of MARS-5 not only on the 
relation between seizure severity and QoL, but also on the 
relation between AED level and QoL. Our findings revealed 
that serum AED level, medication adherence, and QoL positi-
vely correlate with each other in elderly patients with epilepsy. 
Furthermore, we also found that increased seizure severity, 
as determined by LSSS score, was associated with decreased 
medication adherence among elderly patients with epilepsy. 
The positive correlation between medication adherence 
and AED level suggests that the self-reported MARS-5 score 
could be suitable  to assess AED adherence in the elderly 
with epilepsy, which is consistent with previous studies on 
Table 2. The association between MARS-5 score and LSSS score as well as 
serum AED level
B SE β p*
LSSS score -0.09 0.009  -0.33 < 0.0001
Serum AED level 2.68 0.302 0.29 < 0.0001
AED — antiepileptic drug; LSSS — Liverpool Seizure Severity Scale; MARS-5 — Medication Adherence 
Report Scale; SE — standard error. The results were analysed by the multiple linear regression 
method after adjusting for age, sex, marital status, educational years, employment, income, epilep-
sy type and disease duration; *p < 0.05 was considered as statistically significant
Table 3. Results from multiple linear regression analysis that evaluated the association between dependent (QOLIE-31 score and its domains) and indepen-
dent (LSSS score, MARS-5 score and serum AED level) variables
Variables LSSS serum AED level MARS-5
B (SE) β B (SE) β B (SE) β
Seizure concern 0.07 (0.06) 0.05 –1.33 (1.84) –0.03 1.37 (0.21) 0.25*
Cognitive function –0.05 (0.07) –0.03 4.61 (2.29) 0.07 1.58 (0.26) 0.24*
Energy/fatigue –0.07 (0.03) –0.08 0.57 (0.98) 0.02 0.57 (0.11) 0.20*
Emotional wellbeing –0.04 (0.03) –0.06 –0.90 (1.01) –0.03 0.57 (0.12) 0.20*
Social function –0.05 (0.03) –0.05 –0.06 (1.16) –0.01 0.75 (0.13) 0.23*
Medication efficacy –0.05 (0.04) –0.05 0.91 (1.28) 0.03 0.64 (0.15) 0.17*
Overall QoL –0.01 (0.03) –0.02 0.70 (1.05) 0.02 0.46 (0.12) 0.15*
Overall score –0.04 (0.03) –0.04 1.19 (1.05) 0.04 0.93 (0.12) 0.30*
QOLIE-31 — Quality of Life in Epilepsy Inventory-31; LSSS — Liverpool Seizure Severity Scale; MARS-5 — Medication Adherence Report Scale; AED — antiepileptic drug; QoL — quality of life; SE — standard error. The 
results were analysed by the Multiple Linear Regression method adjusted for age, sex, marital status, educational years, employment, income, epilepsy type and disease duration. *p < 0.00625 (Bonferroni cor-
rection with eight comparisons; 0.05/8 = 0.00625) was considered as statistically significant
Figure 1. The proxy effects of MARS-5 score on the quality of life (QoL) in elderly patients with epilepsy. *p < 0.001; LSSS — Liverpool Seizure 
Severity Scale; MARS-5 — Medication Adherence Report Scale; QOL — quality of life
Cognitive functioning
Energy/fatigue
Emotional well being
Social functioning
Medication effects
Seizure worry
Overall quality of life
LSSS
Serum level
MARS-5QOL
�0.316*
0.268*
0.666*
0.586*
�0.015
0.175*
0.021
0.419*0.689*
0.572*
0.598*
0.818*
2X  (df) = 83.826 (27)
X  / df = 3.1052
p-value < 0.001
Comparative Fit Index = 0.974
Goodness of Fit Index = 0.978
Tucker-Lewis Index = 0.957
Normed Fit Index = 0.963
Root Mean Square Error 
of Approximation = 0.052
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epilepsy treatment [25, 37]. Given that serum level measure-
ment is invasive and costly, a MARS questionnaire could be 
used to evaluate patient adherence to treatment. However, 
in contrast to our findings, several studies on patients with 
chronic obstructive pulmonary disease (COPD) and children 
with asthma have suggested that the MARS-5 score is not an 
accurate self-reporting instrument to measure drug adherence 
in those patient cohorts [15, 16]. Furthermore, it has been 
reported that MARS-5 score is not an accurate instrument to 
measure drug adherence in hypertensive patients [14]. The 
contradictions observed between our results and those in the 
abovementioned studies might be due to the type of disease 
and the difference in clinical characteristics, as well as to the 
efficacy of the medication in controlling medical symptoms. 
Our study also indicated that medication adherence 
was inversely correlated with seizure severity. However, this 
finding could have been confounded by several clinical and 
demographic characteristics of the participants. Therefore, 
we adjusted our analyses for confounders such as age, sex, 
marital status, educational years, employment status, income 
level, epilepsy type, and duration of the disease. Interestingly, 
we observed that seizure severity and serum drug level were 
both independently related to medication adherence even after 
adjusting for those confounders. Therefore, our findings show 
that seizure severity and serum AED level are strong predictors 
of medication adherence in patients with epilepsy. 
In this study, we evaluated the association between me-
dication adherence, seizure severity and serum AED level of 
the patients with their QoL. In particular, we found that, after 
controlling clinical and demographic characteristics, medica-
tion adherence was directly associated with the overall score 
of QoL and all its domains, while seizure severity and serum 
AED level did not have a significant correlation with the QoL. 
Serum AED levels are not necessarily associated with QoL 
in patients with epilepsy. That being said it does not provide 
detailed information on patients’ level of adherence over time. 
Moreover, serum AED levels can only be assessed in patients 
who are taking second generation AEDs [40]. Moreover, the 
interpretation of serum AED level depends on the time of 
sampling and the duration of AED therapy. These problems 
limit the usefulness of  the information regarding serum AED 
levels in everyday clinical practice. 
Although our findings did not confirm a significant corre-
lation between seizure severity and QoL, several studies have 
confirmed an inverse relationship between seizure severity 
and QoL in epileptic patients. For example, Harden et al. 
[41] examined a group of women aged 18-45 with refractory 
epilepsy and found that, even when controlling for depres-
sion, seizure severity was inversely correlated with multiple 
domains of QoL. Bautista et al. [42] indicated that quality of 
life for patients with epilepsy was adversely affected by seizure 
severity. Furthermore, Sancho et al. [43] indicated that QoL 
in patients with severe seizures has been consistently shown 
to be worse than for those with mild or moderate seizures.
Moreover, our study indicated that medication adherence 
was positively correlated with QoL. Indeed, AED non-adher-
ence impacted negatively on QoL as a result of poor seizure 
control.  A number of studies have examined the relation-
ship between medication adherence and QoL. However, the 
findings remain controversial. Consistent with our findings, 
several studies have previously demonstrated the beneficial 
effects of medication adherence on improved QoL in epileptic 
patients [10, 44, 45] and other diseases [46, 47]. Loon et al. [47] 
found that adherence to glaucoma medications was associated 
with better QoL. Moreover, medication adherence has been 
reported to be associated with increased QoL in patients with 
epilepsy [44, 45]. However, Martinez et al. [48] could not find 
any significant association between medication adherence and 
QoL in patients with type 2 diabetes. In the study by Saleem 
et al. [21], no relationship was found between medication 
adherence and QoL in hypertensive patients. However, due to 
the conflicting results, it remains unclear whether increased 
seizure severity or decreased QoL is the primary event.
Despite the evidence that medication adherence can im-
prove QoL, it is uncertain whether seizure severity and serum 
AED level can be replaced by medication adherence to predict 
QoL. Our hypothesis was that medication adherence may 
mediate the correlation between seizure severity and QoL, 
as well as serum AED level and QoL. Using the Sobel test to 
test our hypothesis revealed that medication adherence did 
mediate the correlation between seizure severity and QoL. 
This indicates that less severe seizures may be due to incre-
ased medication adherence and eventually lead to increased 
QoL. Moreover, the Sobel test revealed the mediatory effect 
of medication adherence on AED level and QoL, suggesting 
that a higher AED level can be due to increased medication 
adherence resulting in improved QoL. In addition, these results 
were supported by the SEM model, which confirmed the proxy 
effect of medication adherence on the latent score of QoL.
This study revealed that neither seizure severity nor serum 
AED level had a direct effect on the QoL, although there was 
an indirect effect between these variables via medication ad-
herence. Therefore, medication adherence is very important 
to improve QoL in elderly patients with epilepsy, and it should 
be strongly encouraged by physicians.
According to our findings, elderly people with epilepsy 
who are concerned about the impact of epilepsy on their in-
dependence and QoL could potentially control their seizure 
symptoms through medication adherence. Furthermore, there 
is a need to pay more attention to medication management and 
adherence to improve QoL among the elderly with epilepsy. 
As the elderly are prone to multiple comorbidities, they are at 
higher risk of polypharmacy, and therefore may present with 
a higher risk of non-adherence to medication compared to 
the younger population. This results in decreased therapeutic 
benefits for the patient, and increased healthcare expenditure.
There are several strengths of our study, including serum 
AED level measurement to assess medication adherence, 
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a relatively large sample size, and longitudinal design, which 
can help yield firm conclusions. However, some caution is 
necessary in the  interpretation of our findings. Firstly, it is 
likely that the associations between the variables may also be 
partially explained by other confounders that were not con-
trolled for in this study, e.g. unhealthy lifestyle. Secondly, we 
did not assess serum AED level and the QoL at the beginning 
of the study. Therefore, we are unable to discuss the associa-
tion between the changes of medical adherence and quality of 
life throughout the study. Finally, major cognitive and acute 
psychiatric disorders such as depression and anxiety, which 
could be key factors affecting both medication adherence and 
QoL, were excluded from the current study. 
Conclusion
In elderly patients with epilepsy, medication adherence 
significantly correlates with QoL. Given proper medication 
management, the QoL of these patients can be improved. 
Therefore, healthcare providers need to provide an appropriate 
level of support by frequently reviewing drug management 
and monitoring adherence in elderly patients with epilepsy. 
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